{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"CS1 expression levels analyzed from matching bone marrow aspirates (for bone marrow-derived MM cells) and from peripheral blood (for circulating tumor cells) collected from the same participants","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"populationDescription":"All treated participants with matched samples of bone marrow-derived MM cells and circulating MM cells.\n\nCirculating MM cells were not collected for any of the participants.","reportingStatus":"POSTED","timeFrame":"At baseline (screening), during main study therapy (cycle 3 day 1) and at time of progression (up to approximately 54 months)","title":"CS1 Expression Levels in Matched Samples of Bone Marrow-Derived Multiple Myeloma (MM) Cells and Circulating MM Cells","type":"SECONDARY"}